NIH #5R01CA123249-04
Regulation of Serine Protease HtrA1 and Chemoresponse
- Amount
- $304K
- Period
- 2008-04-01 → 2013-01-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at MAYO CLINIC ROCHESTER
Ovarian cancer diagnosis and treatment · Reproductive Medicine
4 total · 0 active
NIH #5R01CA123249-04
Awarded at MAYO CLINIC ROCHESTER
NIH #5R01CA123249-03
Awarded at MAYO CLINIC ROCHESTER
NIH #5R01CA123249-02
Awarded at MAYO CLINIC ROCHESTER
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Differential effects of GPX4 inhibitor on drug-tolerant persister ovarian cancer cells
Gynecologic Oncology · 2026-04-23
BET inhibition disrupts the FOXM1-MYC axis to induce BRCAness and enhance PARP inhibitor response
npj Precision Oncology · 2026-03-12
Cancers · 2025-10-07 · 4 citations
Cancer Research · 2025-09-19
Cancer Research · 2025-09-19
International Journal of Women s Health · 2025-09-01
Role of drug induced nuclear CTSL (nCTSL) in DNA damage response in cancer- therapeutic implicationsPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-01-14 · 1 citations
Case Report: ESR1::CITED2 Fusion in a Malignant Uterine Tumor Resembling Ovarian Sex Cord Tumor
International Journal of Gynecological Pathology · 2025-01-09 · 3 citations
Annals of Oncology · 2024-09-01 · 4 citations